KC
ASBP

Kepos Capital’s Aspire Biopharma ASBP Stock Holding History

Kepos Capital’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-125
Closed -$1.59M – 324
2023
Q2 		$1.59M Buy
+125
New +$1.57M 0.29% 70
2022
Q4 		$7.72M Buy
625
+62
+11% +$759K 1.11% 21
2022
Q3 		$6.84M Hold
563
– – 0.83% 32
2022
Q2 		$6.74M Buy
+563
New +$6.74M 0.62% 54

Other funds holding ASBP

PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
ETH
Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Kepos Capital's ASBP Position: Q3 2023 in Review

Kepos Capital sold out of Aspire Biopharma (ASBP) in Q3 2023, closing a stake of 125 shares — an estimated $1.59M sold.

Kepos Capital first reported a position in ASBP in Q2 2022 and held it in 4 quarters. The position peaked at $7.72M in Q4 2022. 17 funds tracked by Wall St. Rank hold ASBP as of Q3 2023.

  • Kepos Capital reported no remaining Aspire Biopharma position as of Q3 2023 after selling out during the quarter.
  • Kepos Capital sold 125 Aspire Biopharma shares in Q3 2023, an estimated $1.59M.
  • Kepos Capital first reported a position in Aspire Biopharma in Q2 2022 and held it in 4 quarters.
  • Kepos Capital's Aspire Biopharma position peaked at $7.72M in Q4 2022.
  • 17 funds tracked by Wall St. Rank held Aspire Biopharma as of Q3 2023.

Based on Kepos Capital's 13F filing for Q3 2023, filed 14 Nov 2023.